




Revista Española de Cirugía Oral y Maxilofacial

www.revistacirugiaoralymaxilofacial.es



Original

Salivary matrix metalloproteinase-2 as a non-invasive biomarker for oral squamous cell carcinoma: diagnostic and prognostics

K. Hema Shree¹, R. Gayathri^{*2}, Vishnu Priya Veeraraghavan³, J. Selvaraj³
and Pratibha Ramani¹

¹Department of Oral and Maxillofacial Pathology. Saveetha Dental College and Hospitals, Saveetha Institute Medical and Technical Science. Chennai, India. ²Department of Biochemistry. Saveetha Dental College. Chennai, India. ³Department of Biochemistry. Saveetha Dental College and Hospitals, Saveetha Institute Medical and Technical Science. Chennai, India

INFORMACIÓN DEL ARTÍCULO

Historia del artículo:

Recibido: 13 de diciembre de 2024

Aceptado: 17 de enero de 2025

Keywords:

Oral squamous cell carcinoma,
MMP-2, saliva, non-invasive
diagnostics, biomarker, prognosis,
ELISA.

A B S T R A C T

Background: Oral squamous cell carcinoma (OSCC) is a prevalent malignancy characterized by late-stage diagnosis and high recurrence rates, underscoring the need for reliable biomarkers. Matrix metalloproteinase-2 (MMP-2), a zinc-dependent enzyme implicated in extracellular matrix degradation, has shown potential as a biomarker for OSCC progression. Saliva, being non-invasive and accessible, offers a promising medium for MMP-2 assessment.

Objectives: This study aimed to evaluate salivary MMP-2 levels in OSCC patients and healthy controls to determine its diagnostic and prognostic significance.

Methods: This clinical study included 60 participants divided into three groups: healthy controls (n = 20), pre-operative OSCC patients and post-operative OSCC patients (n = 40). Saliva samples were collected, processed, and analyzed for MMP-2 levels using ELISA. Statistical analyses, including ANOVA and post-hoc Tukey tests, were performed to compare groups. Kaplan-Meier survival analysis was used to assess the prognostic impact of MMP-2 expression.

Results: MMP-2 levels were significantly elevated in pre-operative OSCC patients (78.69 ± 2.65 ng/mL) compared to controls (36.20 ± 1.83 ng/mL; $p < 0.0001$). Post-operative patients exhibited reduced but still elevated levels (51.88 ± 4.25 ng/mL), highlighting the partial impact of surgical intervention. Kaplan-Meier analysis revealed poorer survival probabilities in patients with high MMP-2 levels, emphasizing its prognostic value.

Conclusions: Salivary MMP-2 serves as a potential non-invasive biomarker for OSCC diagnosis, disease monitoring, and prognosis. Its incorporation into clinical practice could enhance early detection and treatment planning, improving patient outcomes.

*Autor para correspondencia:

Correo electrónico: gayathri.sdc@saveetha.com (R. Gayathri).

<http://dx.doi.org/10.20986/recom.2025.1586/2024>

La metaloproteinasa-2 de matriz salival como biomarcador no invasivo del carcinoma oral de células escamosas: diagnóstico y pronóstico

R E S U M E N

Palabras clave:

Carcinoma oral de células escamosas, MMP-2, saliva, diagnóstico no invasivo, biomarcador, pronóstico, ELISA.

Antecedentes: El carcinoma oral de células escamosas (OSCC) es una neoplasia prevalente caracterizada por un diagnóstico tardío y altas tasas de recurrencia, lo que subraya la necesidad de biomarcadores fiables. La metaloproteinasa de matriz-2 (MMP-2), una enzima dependiente del zinc implicada en la degradación de la matriz extracelular, ha demostrado su potencial como biomarcador de la progresión del OSCC. La saliva, al ser no invasiva y accesible, ofrece un medio prometedor para la evaluación de la MMP-2.

Objetivos: El objetivo de este estudio es evaluar los niveles de MMP-2 en la saliva de pacientes con OSCC y controles sanos para determinar su importancia diagnóstica y pronóstica.

Métodos: Este estudio clínico incluyó 60 participantes divididos en tres grupos: controles sanos ($n = 20$), pacientes preoperatorios de OSCC y pacientes postoperatorios de OSCC ($n = 40$). Se recogieron, procesaron y analizaron muestras de saliva para determinar los niveles de MMP-2 mediante ELISA. Se realizaron análisis estadísticos, incluyendo ANOVA y pruebas *post hoc* de Tukey, para comparar los grupos. Se utilizó el análisis de supervivencia de Kaplan-Meier para evaluar el impacto pronóstico de la expresión de MMP-2.

Resultados: Los niveles de MMP-2 fueron significativamente elevados en los pacientes preoperatorios de OSCC ($78,69 \pm 2,65$ ng/ml) en comparación con los controles ($36,20 \pm 1,83$ ng/ml; $p < 0,0001$). Los pacientes postoperados mostraron niveles reducidos, pero aún elevados ($51,88 \pm 4,25$ ng/ml), lo que pone de manifiesto el impacto parcial de la intervención quirúrgica. El análisis de Kaplan-Meier reveló peores probabilidades de supervivencia en pacientes con niveles elevados de MMP-2, lo que subraya su valor pronóstico.

Conclusiones: La MMP-2 salival sirve como un biomarcador potencial no invasivo para el diagnóstico del OSCC, la monitorización de la enfermedad y el pronóstico. Su incorporación a la práctica clínica podría mejorar la detección precoz y la planificación del tratamiento, mejorando los resultados de los pacientes.

INTRODUCTION

Oral squamous cell carcinoma (OSCC) is the most common type of oral malignancy, accounting for over 90 % of all oral cancers. It is one of the top ten cancers globally, with a particularly high prevalence in regions where tobacco and areca nut use are widespread¹. Despite advancements in diagnostic and therapeutic approaches, OSCC prognosis remains dismal due to late-stage diagnosis and high recurrence rates. There is an urgent need for early and non-invasive diagnostic markers to improve survival outcomes and enhance the quality of life for patients².

Matrix metalloproteinases (MMPs) are zinc-dependent enzymes crucial for extracellular matrix (ECM) remodeling. Among them, MMP-2 (gelatinase A) is especially significant in cancer progression due to its ability to degrade type IV collagen, a primary component of the basement membrane³. Dysregulated MMP-2 activity is implicated in tumor invasion, angiogenesis, and metastasis, making it a critical player in the malignant behavior of cancers, including OSCC. Its over-expression within the tumor microenvironment underscores

its potential as a biomarker for cancer progression and therapeutic targeting⁴.

Saliva has emerged as a promising diagnostic medium due to its non-invasive, cost-effective, and accessible nature⁵. Recent studies suggest that saliva harbors numerous biomarkers, including MMP-2, which are linked to OSCC progression⁶. Elevated levels of salivary MMP-2 have been associated with enhanced tumor invasion and metastasis, highlighting its potential utility in both diagnosis and prognosis⁷. By evaluating MMP-2 levels in saliva, clinicians could gain insights into the disease state, enabling early detection and more precise disease monitoring⁸.

Currently, OSCC diagnostics heavily rely on invasive methods such as biopsy and histopathological evaluation, which are often uncomfortable for patients and limited in detecting early lesions⁹. These limitations necessitate the exploration of molecular biomarkers like MMP-2, which offer a minimally invasive and effective alternative. However, despite its potential, the clinical utility of salivary MMP-2 requires further validation to establish its reliability and practical application in routine diagnostics¹⁰.

This study aims to evaluate salivary MMP-2's potential as a reliable biomarker for oral squamous cell carcinoma, focusing on its role in predicting patient outcomes and long-term survival. By examining its expression levels and their association with disease progression, the study seeks to establish MMP-2 as a noninvasive tool to aid in early risk stratification and personalized treatment planning.

METHODOLOGY

Study design and sample collection

This study was conducted to evaluate MMP-2 levels in the saliva of oral squamous cell carcinoma (OSCC) patients. Participants were categorized into three groups: Control, Pre-operative (Pre-op), and Post-operative (Post-op). The Control group consisted of healthy individuals with no history of OSCC or systemic diseases. The Pre-op group included patients diagnosed with OSCC before undergoing any form of treatment, while the Post-op group consisted of OSCC patients who had undergone surgical tumor removal. Sample size estimation for this longitudinal study was based on previous literature, considering a medium effect size ($f = 0.25$), significance level ($\alpha = 0.05$), power ($1 - \beta = 0.80$), and three study groups (Pre-op, Post-op, and Control).

A total of 60 participants were recruited for the study and categorized into two primary groups. The Control group included 20 healthy individuals with no history of OSCC or systemic diseases, while the remaining 40 participants comprised the Pre-operative (Pre-op) OSCC group. These same patients were reassessed post-surgery to form the Post-operative (Post-op) OSCC group. Unstimulated saliva samples were collected from all participants both preoperatively and postoperatively under standardized conditions to ensure uniformity. The collected samples were promptly processed and stored at -80°C to preserve their integrity until further analysis.

Salivary MMP-2 levels were quantified using enzyme-linked immunosorbent assay (ELISA). The assay was conducted following the manufacturer's protocol, ensuring reliable and reproducible results. Statistical analyses were performed using SPSS software. A one-way analysis of variance (ANOVA) was conducted to compare MMP-2 levels across the three groups, and post-hoc Tukey tests were used to determine specific differences between groups. Additionally, Kaplan-Meier survival analysis was employed to evaluate the prognostic significance of MMP-2 expression in OSCC patients.

Saliva samples were collected from all participants under standardized conditions to ensure consistency after obtaining ethical clearance from the institutional board with a reference number of SRB/SDC/PhD/OPATH-2102/21/TH-O06. Participants were asked to abstain from eating, drinking, or smoking for at least one hour before collection. Unstimulated saliva was allowed to pool in the mouth and was then expectorated into sterile collection tubes. This approach minimized variability in salivary composition due to external factors.

Sample processing

Immediately after collection, saliva samples were placed on ice and transported to the laboratory for processing. The samples were centrifuged at 3000 rpm for 15 minutes at 4°C to remove cellular debris and other particulates. The clear supernatant was carefully separated and aliquoted into sterile microcentrifuge tubes to avoid contamination. These aliquots were stored at -80°C until analysis to preserve the stability of MMP-2.

Quantification of MMP-2 Using ELISA

The levels of MMP-2 in saliva were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit, following the manufacturer's protocol. First, the ELISA reagents, including capture antibodies, detection antibodies, substrate solutions, and stop solutions, were prepared as instructed. Saliva samples were diluted in the provided assay buffer to ensure MMP-2 concentrations were within the dynamic detection range of the kit.

A 96-well microplate pre-coated with anti-MMP-2 capture antibodies was used. Diluted saliva samples, standards with known MMP-2 concentrations, and blank controls were added in duplicate to their respective wells. The plate was incubated at room temperature for the specified duration, allowing MMP-2 to bind to the capture antibodies. After incubation, the plate was washed thoroughly with the provided wash buffer to remove unbound components.

Next, a detection antibody conjugated with an enzyme (e.g., horseradish peroxidase) was added to each well, followed by incubation to enable specific binding to the captured MMP-2. After further washing, a substrate solution (e.g., tetramethylbenzidine, TMB) was added to initiate a colorimetric enzymatic reaction. The intensity of the color, proportional to the MMP-2 concentration, was stabilized by adding a stop solution (e.g., sulfuric acid). The optical density of each well was measured at 450 nm using a microplate reader. The obtained absorbance values were used to calculate MMP-2 concentrations.

Data analysis

The absorbance values were interpolated onto a standard curve generated using known MMP-2 concentrations provided with the ELISA kit. The MMP-2 levels in saliva were calculated for each group and expressed as mean \pm standard deviation (SD). Statistical analysis was conducted using the SPSS software version 23. One-way analysis of variance (ANOVA) was used to compare MMP-2 levels among the three groups, followed by post-hoc pairwise comparisons to assess differences between specific groups. A p-value of <0.05 was considered statistically significant, indicating meaningful differences in MMP-2 levels between groups.

Survival analysis

Pre-operative MMP-2 expression levels were analyzed to establish a significant cutoff for stratifying patients into

low and high expression groups. The median value was calculated and utilized as an initial reference for this stratification, thereby providing a foundational yet reliable dataset division. A Receiver Operating Characteristic (ROC) curve was constructed to further refine this cutoff by incorporating clinical outcomes or related variables, thereby identifying the optimal threshold that maximized the balance between sensitivity and specificity. A comprehensive review of relevant literature was conducted, which revealed comparable cutoff values that supported both the biological and clinical relevance of the proposed threshold. Based on these findings, a cutoff was selected that balanced simplicity, clinical applicability, and conformity with existing research. The cutoff was validated by comparing clinical outcomes, sensitivity, and specificity across the respective groups.

Kaplan-Meier survival analysis was employed to assess the impact of Matrix Metalloproteinase-2 (MMP-2) expression on patient survival outcomes. Patients were stratified into two groups based on MMP-2 expression cut off levels: low and high. Survival probabilities were calculated from baseline (0 months) and monitored over a defined follow-up period, with time intervals recorded at 3, 4, 7, and 9 months. The survival probabilities were plotted for each group, allowing a comparative analysis of survival trends. Statistical significance between the groups was evaluated using the log-rank test, which determines whether observed survival differences were due to random variation or were statistically significant. The analysis was performed using specialized statistical software to ensure precision and reproducibility, offering valuable insights into the prognostic implications of MMP-2 expression levels in cancer progression.

Ethical considerations

The study protocol was approved by the institutional ethics committee, ensuring adherence to ethical research practices. Written informed consent was obtained from all participants prior to sample collection, and patient confidentiality was strictly maintained throughout the study. Participants were informed of the study's objectives, and their rights to withdraw at any stage were respected.

Quality control

Quality control measures were implemented throughout the experiment to ensure reliable results. All ELISA assays were performed in duplicate to minimize variability and ensure reproducibility. Negative and blank controls were included in every assay to detect non-specific binding or contamination. Internal controls were used to validate the assay's accuracy and consistency. Additionally, all laboratory personnel involved in the assay adhered to standardized operating procedures to maintain high experimental reliability.

This methodology, employing ELISA as a sensitive and specific tool, enabled the precise quantification of MMP-2 in saliva samples, thereby ensuring the reliability of the results in assessing its potential as a biomarker for OSCC diagnosis and treatment monitoring.

RESULTS

Table I descriptive data highlight distinct group characteristic, with elevated MMP-2 levels in the pre-operative group (mean: 75.6 ng/ml) reflecting active disease and tumor aggressiveness. Post-operative levels (mean: 50.5 ng/ml) indicate surgical efficacy but suggest the need for adjunct therapies, while controls showed baseline levels (mean: 36.2 ng/ml). The pre-op group was older (mean age: 58 years) and predominantly male (60 %), with advanced stages (Stage III/IV) and well-differentiated squamous cell carcinoma (55 %). These findings underscore the utility of MMP-2 as a biomarker for OSCC diagnosis, monitoring, and treatment planning.

Table I. Clinical and Demographic Characteristics of Study Groups and MMP-2 Levels.

Variable	Pre-op Group	Post-op Group	Control Group
Age			
Mean	58 years	-	46 years
Std Deviation	6 years	-	4 years
Min Age	50 years	-	40 years
Max Age	65 years	-	50 years
Gender			
Male	60 %	N/A	55 %
Female	40 %	N/A	45 %
Ethnicity			
Asian	75 %	N/A	70 %
Other	25 %	N/A	30 %
MMP-2 Levels			
Mean (ng/ml)	75.6	50.5	36.2
Std Deviation (ng/ml)	22	10	4.5
Min (ng/ml)	44.7	36.6	33.5
Max (ng/ml)	119.3	57.8	39.9
Disease Stage			
Stage I	20 %	N/A	N/A
Stage II	30 %	N/A	N/A
Stage III	25 %	N/A	N/A
Stage IV	25 %	N/A	N/A
Differentiation Type			
WDSCC	55 %	N/A	N/A
MDSCC	30 %	N/A	N/A
PDSCC	15 %	N/A	N/A

The levels of MMP-2 in saliva were measured using ELISA (Enzyme-Linked Immunosorbent Assay) in three groups: Control, Pre-operative (Pre-op), and Post-operative (Post-op). The Control group, representing healthy individuals, exhibited significantly lower MMP-2 levels (Mean \pm SD: 36.20 \pm 1.83 ng/ml). These levels serve as a baseline for normal MMP-2 expression in non-cancerous conditions. In contrast, the Pre-op group displayed the highest MMP-2 levels (Mean \pm SD: 78.69 \pm 2.65 ng/ml), highlighting the biomarker's association with OSCC. Elevated MMP-2 in this group highlights its role in extracellular matrix degradation and tumor invasion, processes critical for OSCC progression (Table II, Figure 1).

In the Post-op group (Mean \pm SD: 51.88 \pm 4.25 ng/ml), MMP-2 levels showed a significant decrease compared to the Pre-op group, indicating that the surgery had an effect on tumor-related activity. However, these levels did not fully return to the baseline seen in the Control group, suggesting that MMP-2 expression did not completely resolve. The remaining elevation could be due to ongoing disease activity or inflammation after the surgery.

Statistical analysis revealed significant differences in MMP-2 levels across the three groups (F-statistic = 7.79, $p < 0.05$). Pairwise comparisons confirmed a highly significant difference between the Control and Pre-op groups ($p = 0.0001$), reinforcing the role of MMP-2 as a reliable marker of OSCC presence. Additionally, the significant difference between the Post-op and Pre-op groups ($p = 0.03$) demonstrates the reduction in tumor-associated activity following surgery. While the MMP-2 levels in the Post-op group remain higher than in the Control group, the difference is not statistically significant ($p = 0.18$). This suggests that the levels might trend toward normalization after surgery, but further studies with larger sample sizes are needed to confirm this observation.

Table II. ANOVA analysis of the study group.			
Groups	Mean \pm SD (ng/ml)	F-statistic	p-Value
Control	36.20 \pm 1.83	7.79	<0.05
Pre-op	78.69 \pm 2.65		
Post-op	51.88 \pm 4.25		




Figure 1. Provides a visual representation of the mean MMP-2 levels, highlighting the stark differences between the control, pre-operative, and post-operative group.

The post-hoc Tukey comparison (Table III) highlights significant differences in MMP-2 levels across the study groups, with the highest levels observed in the Pre-op group. This underscores MMP-2's role as a biomarker for disease severity, with partial reduction Post-op reflecting surgical efficacy.

A suggested cutoff value for MMP-2 expression levels, based on the range of 44.68 to 119.31 ng/ml, is 75 ng/ml. This value is slightly above the median of 70.25 ng/ml, which initially stratifies the dataset into low and high expression groups, and offers a practical midpoint within the observed distribution. While the ROC-derived optimal cut-off (0.9174525774375621) appears to be a normalized or transformed value, the proposed cut-off of 75 ng/ml aligns with a straightforward approach that balances simplicity and clinical applicability (Figure 2 and Figure 3). Furthermore, values reported in the literature for MMP-2 expression cut-offs have been observed to fall within a similar range, supporting the biological and clinical relevance of this selection.

Matrix metalloproteinase-2 (MMP-2) plays a critical role in cancer progression, and its expression is often linked to poor prognosis. The Kaplan-Meier survival analysis compared survival probabilities between patients with low and high MMP-2 levels. For the high MMP-2 group, survival probabilities

decreased significantly over time, starting at 1.0 at baseline (0 months), dropping to 0.9375 at 3 months, 0.875 at 4 months, 0.8125 at 7 months, and reaching 0.75 at 9 months (Table IV, Figure 4). These results indicate a steady decline in survival over time for patients with elevated MMP-2 levels. In contrast, the low MMP-2 group showed comparatively better survival probabilities. The steep decline in survival probabilities for the high MMP-2 group suggests that elevated MMP-2 levels are associated with significantly worse outcomes, highlighting its potential as a prognostic marker and a candidate for therapeutic targeting.

Table III. Post hoc Tukey comparison between the study groups.

Group 1	Group 2	Mean Difference	p-Value
Control	Post-op	0.0559	0.18
Control	Pre-op	0.1623	0.0001
Post-op	Pre-op	0.1064	0.03




Figure 2. Survival analysis using Kaplan Meier.




Figure 3. ROC curve for cut-off analysis.




Figure 4. Kaplan Meier for survival analysis.

Table IV. Survival probability analysis.		
	Time (months)	Survival Probability
0	0.0	1.0
1	3.0	0.9375
2	4.0	0.875
3	7.0	0.8125
4	9.0	0.75

DISCUSSION

Matrix Metalloproteinase-2 (MMP-2) has been investigated as a potential biomarker in understanding the pathogenesis, diagnosis, and prognosis of oral squamous cell carcinoma (OSCC)¹¹. This study demonstrated a significant variation in salivary MMP-2 levels across three groups (Control, Pre-operative, and Post-operative), underscoring its diagnostic and prognostic relevance.

The significant elevation of MMP-2 in the Pre-operative group compared to the Control group highlights its robust association with OSCC progression. Elevated MMP-2 is known to degrade extracellular matrix components, facilitating tumor invasion, angiogenesis, and metastasis. This finding is consistent with earlier reports by Monea et al. (2022), who demonstrated that high salivary MMP-2 levels correlate with increased tumor invasiveness and poor clinical outcomes in OSCC patients^{6,12}. Furthermore, the post-operative reduction in MMP-2 levels signifies the effectiveness of surgical intervention in curbing tumor-associated molecular activity. However, the incomplete normalization of MMP-2 levels aligns with studies by Patel BP et al. (2018), suggesting the persistence of residual disease activity or inflammation post-surgery¹³. This residual elevation underscores the necessity of adjunct therapies such as radiotherapy or targeted molecular treatments to achieve comprehensive tumor eradication¹⁴.

Notably, these levels differ from previously reported baseline values for healthy individuals, such as the approximately 2 ng/ml reported by Dalirsani et al. (2019)¹⁵. This discrepancy could arise from differences in study methodologies, population demographics, or assay sensitivity and specificity. Dalirsani et al. observed no significant differences in MMP-2 levels between OSCC patients and healthy controls in head and neck squamous cell carcinoma (HNSCC), suggesting MMP-2 may not always be a definitive biomarker across all populations or settings¹⁵. However, our study focuses specifically on OSCC, a distinct subset of HNSCC. It uses a standardized saliva sampling protocol under controlled conditions, which may contribute to higher MMP-2 levels in both patient and control groups.

The elevated MMP-2 levels in the Pre-op group align with its known role in extracellular matrix degradation and tumor invasion. The significant reduction in the Post-op group ($p = 0.03$) underscores the potential impact of surgical intervention on tumor-associated activity. However, the inability of Post-op levels to return fully to baseline might reflect persistent subclinical disease activity or postsurgical inflammation.

The Kaplan-Meier survival analysis further supports the prognostic value of MMP-2 in OSCC. Patients with high salivary MMP-2 levels exhibited a steady decline in survival probabilities, with significant drops noted at 3 months (93.75 %) and 9 months (75 %). These findings align with data reported by Patel BP et al. (2005), who observed that increased MMP-2 expression was associated with poor survival due to enhanced tumor aggressiveness and metastatic potential¹⁶. Conversely, patients with low MMP-2 levels demonstrated comparatively better survival probabilities, underscoring its potential as a prognostic indicator. The survival trends highlight the importance of incorporating MMP-2 level assessments into routine OSCC management to stratify patients into risk categories and tailor treatment approaches accordingly¹⁷.

Clinically, the use of ELISA for quantifying salivary MMP-2 offers a non-invasive, sensitive, and specific method for OSCC diagnosis and monitoring. The precise quantification provided by ELISA allows for early detection and tracking of treatment efficacy¹⁸. These findings are consistent with recent literature emphasizing the role of salivary biomarkers in enhancing diagnostic accuracy and reducing reliance on invasive tissue biopsies¹⁹.

Additionally, the partial reduction of MMP-2 in the post-operative group underscores the need for multi-modal therapeutic strategies. Adjunct therapies targeting MMP-2 activity, such as MMP inhibitors, have shown promise in preclinical studies for reducing tumor progression and improving survival outcomes²⁰. Moreover, long-term follow-up and periodic monitoring of MMP-2 levels could aid in early detection of recurrence, ensuring timely interventions²¹. Integrating MMP-2 measurements into routine care could enhance OSCC management by aiding early detection and monitoring of treatment outcomes.

Furthermore, the findings of this study emphasize the emerging role of salivary biomarkers like MMP-2 in advancing personalized medicine for OSCC. The non-invasive nature of saliva collection, combined with the high sensitivity of ELISA, makes it an ideal approach for regular patient monitoring²². Recent advancements in salivary diagnostics, such as multiplex assays and point-of-care devices, can further enhance the utility of MMP-2 assessment in clinical settings^{23,24}. Incorporating MMP-2 as part of a salivary biomarker panel, alongside other markers like IL-6 and VEGF, could provide a more comprehensive understanding of tumor biology and improve the predictive accuracy for treatment response and survival outcomes^{25,26}. By leveraging these tools, clinicians can better stratify patients, optimize treatment protocols, and ultimately improve the quality of life and survival rates for OSCC patients. The limitations of this study, including the reduced sample size, limited controls, and lack of detailed information on the evolution of the cases, may affect the generalizability and prognostic inference of the findings. A larger sample size, more comprehensive control group data, and detailed follow-up information would strengthen the conclusions and provide a clearer understanding of the disease progression and treatment outcomes.

Future scope

Salivary MMP-2 has significant potential to enhance the early diagnosis, treatment monitoring, and prognosis of OSCC. Integrating this biomarker into clinical workflows could enable non-invasive detection, guide personalized therapeutic strategies, and improve monitoring of disease progression and recurrence. Advancements in diagnostic technologies and multi-biomarker panels may further optimize its utility, while research into MMP-2-targeted therapies could reduce tumor aggressiveness and recurrence. These efforts collectively aim to improve survival outcomes and quality of life for OSCC patients.

CONCLUSION

This study highlights the potential of salivary MMP-2 as a biomarker for oral squamous cell carcinoma (OSCC). The observed elevation of MMP-2 levels in the pre-operative group highlights its involvement in tumor progression, while

the reduction in levels following surgery reflects the effect of the intervention, albeit without a return to baseline. These results indicate a possible role for MMP-2 in the detection and monitoring of OSCC. However, given the study's limitations, including sample size and scope, further research in larger, more diverse populations is necessary to confirm its diagnostic and prognostic value and establish its clinical utility.

PUBLICATION ETHICS

The study has been approved by the ethics committee with approval number IHEC/SDC/PhD/OPATH-2112/24/262.

CONFLICT OF INTEREST

There is no conflict of interest among the authors.

FUNDING SOURCE

There is no funding source to disclose.

REFERENCES

1. Badwelan M, Muaddi H, Ahmed A, Lee KT, Tran SD. Oral Squamous Cell Carcinoma and Concomitant Primary Tumors, What Do We Know? A Review of the Literature. *Curr Oncol*. 2023;30(4):3721-34. DOI: 10.3390/curroncol30040283.
2. Suri S, Boora GS, Kaur R, Chauhan A, Ghoshal S, Pal A. Recent advances in minimally invasive biomarkers of OSCC: from generalized to personalized approach. *Front Oral Health*. 2024;5:1426507. DOI: 10.3389/froh.2024.1426507.
3. Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. *Int J Mol Sci*. 2020;21(24):9739. DOI: 10.3390/ijms21249739.
4. Maheswari TU, Nivedhitha MS. Study to explore the significance of saliva as a diagnostic tool to detect microRNA in oral potentially malignant disorders. *J Adv Pharma Educ Res*. 2017;7(3):278-82.
5. Oliveira Neto NF, Caixeta RAV, Zerbinati RM, Zarpellon AC, Caetano MW, Pallos D, et al. The Emergence of Saliva as a Diagnostic and Prognostic Tool for Viral Infections. *Viruses*. 2024;16(11):1759. DOI: 10.3390/v16111759.
6. Monea M, Pop AM. The use of salivary levels of matrix metalloproteinases as an adjuvant method in the early diagnosis of oral squamous cell carcinoma: a narrative literature review. *Current Issues in Molecular Biology*. 2022;44(12):6306-22.
7. Ghallab NA, Shaker OG. Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions. *Clin Oral Investig*. 2017;21(3):937-47. DOI: 10.1007/s00784-016-1846-8.
8. Zhang C, Man DP, Ma SM, Cao SW, Li DW. [Expressions and significances of CD147, OPN and MMP-2 in oral squamous cell carcinoma]. *Sichuan Da Xue Xue Bao Yi Xue Ban*. 2012;43(5):683-6.
9. Carreras-Torras C, Gay-Escoda C. Techniques for early diagnosis of oral squamous cell carcinoma: Systematic review. *Med Oral Patol Oral Cir Bucal*. 2015;20(3):e305-15. DOI: 10.4317/medoral.20347.
10. Yakob M, Fuentes L, Wang MB, Abemayor E, Wong DT. Salivary biomarkers for detection of oral squamous cell carcinoma - current state and recent advances. *Curr Oral Health Rep*. 2014;1(2):133-41. DOI: 10.1007/s40496-014-0014-y.
11. Wong TS, Gao W, Li ZH. Matrix metalloproteinase family as molecular biomarkers in oral squamous cell carcinoma. *Biomarkers in Cancer*. 2015.
12. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. *Head Neck*. 2007;29(6):564-72. DOI: 10.1002/hed.20561.
13. Yamada S, Yanamoto S, Naruse T, Matsushita Y, Takahashi H, Umeda M, et al. Skp2 Regulates the Expression of MMP-2 and MMP-9, and Enhances the Invasion Potential of Oral Squamous Cell Carcinoma. *Pathol Oncol Res*. 2016;22(3):625-32. DOI: 10.1007/s12253-016-0049-6.
14. Patel BP, Shah PM, Rawal UM, Desai AA, Shah SV, Rawal RM, et al. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. *J Surg Oncol*. 2005;90(2):81-8. DOI: 10.1002/jso.20240.
15. Dalirsani Z, Pakfetrat A, Delavarian Z, Hashemy SI, Mostaan LV, Abdollahnejad M, et al. Comparison of matrix metalloproteinases 2 and 9 levels in saliva and serum of patients with head and neck squamous cell carcinoma and healthy subjects. *Int J Cancer Manag*. 2019;12(5):e90249. DOI: 10.5812/ijcm.90249.
16. Monea M, Pop AM. The use of salivary levels of matrix metalloproteinases as an adjuvant method in the early diagnosis of oral squamous cell carcinoma: a narrative literature review. *Curr Issues Mol Biol*. 2022;44(12):6306-22. DOI: 10.3390/cimb44120430.
17. Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V, Lara-Riegos J, et al. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. *Front Oncol*. 2019;9:1370. DOI: 10.3389/fonc.2019.01370.
18. Rebaudi F, De Rosa A, Greppi M, Pistilli R, Pucci R, Govoni FA, et al. A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans. *Front Immunol*. 2023;14:1216107. DOI: 10.3389/fimmu.2023.1216107.
19. Aparna J, Smiline-Girija AS, Paramasivam A, Vijayashree-Priyadharsini J. Deciphering the genetic alterations in matrix metalloproteinase gene family and its putative association with head and neck squamous cell carcinoma. *Mol Biol Res Commun*. 2021;10(1):13-22. DOI: 10.22099/mbrc.2020.38344.1544.
20. Zhang Y, Wang C, Mizukami H, Itoh H, Kusama M, Ozawa K, et al. Increased expression and activation of matrix metalloproteinase-2 (MMP-2) in O-1N: hamster oral squamous cell carcinoma with high potential lymph node metastasis. *J Exp Clin Cancer Res*. 2006;25(3):417-23.
21. Tsai CH, Hsieh YS, Yang SF, Chou MY, Chang YC. Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors: preliminary observations. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2003;95(6):710-6. DOI: 10.1067/moe.2003.121.
22. Li Y, Ou Y, Fan K, Liu G. Salivary diagnostics: opportunities and challenges. *Theranostics*. 2024;14(18):6969-90. DOI: 10.7150/thno.100600.
23. Miller CS, Foley JD, Bailey AL, Campell CL, Humphries RL, Christodoulides N, et al. Current developments in salivary diagnostics. *Biomark Med*. 2010;4(1):171-89. DOI: 10.2217/bmm.09.68.
24. Krishnasree RJ, Jayanthi P, Varun BR, Ramani P, Rathy R. Evaluation of salivary MMP-9 in Oral Squamous Cell Carcinoma using Enzyme Linked Immunosorbent Assay - A Pilot Study. *Oral Maxillofac Pathol J*. 2023;14(2):190-3.
25. Zheng QK, Yin Q, Zhang N, Sun ZG. Clinical and prognostic features of MMP-2 and VEGF in AEG patients. *Open Med (Wars)*. 2021;16(1):786-94. DOI: 10.1515/med-2021-0252.
26. Hema Shree K, Ramani P, Sherlin H, Sukumaran G, Jeyaraj G, Don KR, et al. Saliva as a Diagnostic Tool in Oral Squamous Cell Carcinoma - a Systematic Review with Meta Analysis. *Pathol Oncol Res*. 2019;25(2):447-53. DOI: 10.1007/s12253-019-00588-2.